Physician
New Lexington Clinic, PSC
New Lexington Clinic, PSC was paid $1.12M by Medicaid between Jan 2018 and Dec 2024, across 83 billing codes. Its largest line is 84443, Thyroid stimulating hormone (TSH) — 12% of everything it billed.
33Billing provider infoNEW LEXINGTON CLINIC, PSC
LEXINGTON, KY 40504
LEXINGTON, KY 40504
33aNPI1144321951assigned 09/26/2006
33bProvider typeClinical Pathology Physician
28Total paid$1.12M
24GClaims154,652
24DCodes billed83
24AFirst – last monthJan 2018 – Dec 2024
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 28,322 | $251K | |
| 2019 | 25,706 | $198K | |
| 2020 | 21,278 | $139K | |
| 2021 | 21,552 | $138K | |
| 2022 | 23,463 | $179K | |
| 2023 | 23,243 | $170K | |
| 2024incomplete | 11,088 | $46K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 84443 | Thyroid stimulating hormone (TSH) | 12% | 12,294 | 11,554 | $135K |
| 80053 | Comprehensive metabolic panel | 12% | 19,538 | 17,879 | $130K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 8.8% | 19,996 | 18,125 | $99K |
| 80061 | Lipid panel | 8.7% | 11,847 | 11,143 | $98K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 7.1% | 4,247 | 4,006 | $79K |
| 83036 | Hemoglobin; glycosylated (A1C) | 3.6% | 7,478 | 6,997 | $41K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 3.5% | 682 | 611 | $39K |
| 82607 | 3.1% | 3,768 | 3,531 | $35K | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | 3.0% | 1,453 | 1,381 | $34K |
| 87086 | Culture, bacterial; quantitative colony count, urine | 2.1% | 5,270 | 4,730 | $23K |
| 82746 | 2.0% | 2,589 | 2,436 | $23K | |
| 84439 | 1.8% | 3,375 | 3,143 | $20K |
71 more codes
| 84153 | 1.7% | 1,356 | $20K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 1.7% | 521 | $19K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 1.7% | 518 | $19K |
| 87070 | 1.6% | 2,488 | $18K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 1.5% | 445 | $17K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | 1.4% | 426 | $16K |
| 80050 | General health panel | 1.3% | 555 | $14K |
| 80074 | 1.2% | 343 | $13K | |
| 82728 | 1.2% | 1,828 | $13K | |
| 80048 | Basic metabolic panel (calcium, ionized) | 1.2% | 3,074 | $13K |
| 87186 | <1% | 2,545 | $11K | |
| 87077 | <1% | 2,527 | $10K | |
| 83550 | <1% | 2,061 | $10K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 295 | $9K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 295 | $9K |
| 83540 | <1% | 2,267 | $8K | |
| 84403 | <1% | 357 | $7K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 513 | $7K |
| 83735 | <1% | 1,744 | $7K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 14,941 | $7K |
| 82570 | <1% | 2,354 | $6K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 337 | $6K |
| 82043 | <1% | 1,998 | $6K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 317 | $6K |
| 84702 | <1% | 399 | $6K | |
| 86140 | <1% | 1,446 | $5K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 206 | $5K |
| 85652 | <1% | 2,588 | $5K | |
| 80076 | <1% | 659 | $4K | |
| 81001 | <1% | 2,202 | $4K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 247 | $4K |
| 84550 | <1% | 1,201 | $3K | |
| 82784 | <1% | 285 | $3K | |
| 87081 | <1% | 474 | $3K | |
| 82565 | <1% | 899 | $3K | |
| 83690 | <1% | 592 | $3K | |
| 86038 | <1% | 288 | $3K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 55 | $3K |
| 83970 | <1% | 179 | $3K | |
| 86803 | <1% | 250 | $3K | |
| 81015 | <1% | 1,288 | $2K | |
| G0472 | Hepatitis c antibody screening, for individual at high risk and other covered indication(s) | <1% | 125 | $2K |
| 84460 | <1% | 605 | $2K | |
| 87340 | <1% | 237 | $2K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 113 | $2K |
| 84481 | <1% | 162 | $2K | |
| 84450 | <1% | 469 | $2K | |
| 87205 | <1% | 561 | $2K | |
| 86255 | <1% | 157 | $2K | |
| 85027 | <1% | 377 | $2K | |
| 82150 | <1% | 317 | $2K | |
| 81513 | <1% | 12 | $1K | |
| 86431 | <1% | 343 | $1K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 43 | $1K |
| 86235 | <1% | 28 | $1K | |
| 86592 | <1% | 229 | $941.36 | |
| 82248 | <1% | 277 | $865.68 | |
| 83001 | <1% | 54 | $767.24 | |
| 82670 | <1% | 26 | $726.81 | |
| 85610 | <1% | 288 | $643.51 | |
| 87522 | Neg quan hep c or qual rna | <1% | 13 | $634.56 |
| 86480 | <1% | 12 | $532.64 | |
| 83516 | <1% | 13 | $353.00 | |
| 86160 | <1% | 14 | $261.67 | |
| 82274 | <1% | 27 | $259.11 | |
| 86376 | <1% | 14 | $203.57 | |
| 86800 | <1% | 13 | $203.19 | |
| 83002 | <1% | 15 | $182.88 | |
| 82550 | <1% | 30 | $158.55 | |
| 83525 | <1% | 13 | $125.73 | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 165 | $118.60 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialCRAIK, KENNETH (CHIEF FINANCIAL OFFICER)
Parent organizationNEW LEXINGTON CLINIC, PSC
| Provider | Location | Paid |
|---|---|---|
| New Lexington Clinic, PSC | Lexington, KY | $12K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.